Understanding brain function requires understanding neural circuits at the level of specificity at which they operate. While recent years have seen the development of a variety of remarkable molecular tools for the study of neural circuits, their utility is currently limited by the inability to deploy them in specific elements of native neural circuits, i.e. particular neuronal subtypes. One can obtain a degree of specificity with neuron-specific promoters, but native promoters are almost never sufficiently specific restricting this approach to transgenic animals. We recently showed that one can obtain transgenic mice with augmented anatomical specificity in targeted brain regions by identifying cis-regulatory elements (i.e. enhancers) uniquely active in those brain regions and combining them with a heterologous promoter, an approach we call EDGE (Enhancer-Driven Gene Expression). Here we extend this strategy to the generation of viral (rAAV) vectors, showing that when combined with the right minimal promoter they largely recapitulate the specificity seen in the corresponding transgenic lines in wildtype animals, even of another species. Because active enhancers can be identified in any tissue sample, this approach promises to enable the kind of circuit-specific manipulations in any species. This should not only greatly enhance our understanding of brain function, but may one day even provide novel therapeutic avenues to correct the imbalances in neural circuits underlying many disorders of the brain.
Introduction
The mammalian brain is the most complex biological structure known, with innumerable distinct cell types differing in cytoarchitecture, electrophysiological properties, gene expression and connectivity 1, 2 . Recent years have seen the development of truly revolutionary molecular tools that allow neuroscientists to elucidate precise neural connectivity 3 and monitor 4 and manipulate [5] [6] [7] neural activity. However, optimal use of these tools to examine the functional circuitry of the brain requires the ability to deliver them specifically to particular elements of neural circuits (i.e. neuronal cell types), rather than as a nonspecific bolus affecting all of the neurons in a brain area. The use of molecular genetics is the only method by which one can perform truly cell-type specific manipulations, as evidenced by a variety of studies using transgenic animals expressing transgenes from neuronal promoters (genomic regions just upstream of the transcriptional start site) 8, 9 .
However, such approaches are limited by the fact that because genes are expressed in a variety of cell types in the brain, promoters are not specific to a single cell type. While estimates vary 10 , there are many more cis-regulatory elements (i.e. enhancers and repressors, distal genomic regions which help regulate where and when promoters transcribe RNA) than promoters, suggesting that enhancers may be more specific. This led us to take an approach to the generation of molecular genetic tools with augmented specificity that we call EnhancerDriven Gene Expression (EDGE). It is based upon identifying the cis-regulatory elements uniquely active in particular brain regions and combining them with a heterologous minimal promoter. When we used this strategy to make transgenic mice, they were indeed significantly more specific than the presumed parent gene, often driving expression in particular sets of neurons in the brain region they were derived from 11 .
However, while transgenic animals are powerful tools for the analysis of neural circuits, they do have some serious drawbacks. They are costly in both time and resources, can be subject to insertional effects 12, 13 , and are most practical in a limited number of species. Moreover, while they are often excellent models of disease, transgenic technologies are far from therapeutic applications. Recombinant adeno-associated viral vectors (rAAVs) can overcome many of the above issues. They can be made relatively quickly, generally do not insert into the genome, and can be used in a variety of species 14 including humans and therefore have clinical potential as well [15] [16] [17] [18] . However, efforts to generate cell-specific viral vectors have been largely unsuccessful to date [19] [20] [21] , with a few notable exceptions 22, 23 . This is due in large part to the fact that one can add relatively little genetic material to the relatively small genomes of rAAVs, putting most native promoters out of reach. However, most enhancers are much smaller than promoters, raising the intriguing possibility of targeting specific neuronal cell types in any species by adapting the EDGE strategy to viral vectors. Towards this end, we present results showing the generation of EDGE viral vectors specifically expressing in particular neurons of the entorhinal cortex (EC) in two different species of wildtype animals.
Results

Optimization of rAAV design for Enhancer-Driven Gene Expression
Because one can obtain some degree of apparent specificity with rAAVs by means other than transcriptional regulation (e.g. serotype, precise injections of minute quantities), we took steps to ensure that any observed specificity comes from the enhancer element used. First and foremost, we used an enhancer specific to a known subset of neurons in the entorhinal cortex 11 in transgenic animals and analyzed whether the rAAV construct could match this specificity. Figure 1A shows the expression pattern obtained from crossing one of the MEC13-53 tTA driver lines to a payload line expressing the helper transgenes for the ΔG-rabies monosynaptic tracing system 11 . Expression in this cross was limited to reelin-positive (RE+), calbindin-negative (CB-) excitatory projection neurons in LII of the medial and lateral EC (i.e. stellate and fan cells, respectively [24] [25] [26] ). Second, because the distinct tropisms of the various serotypes of AAV 14, 27 is a potential confound, we used a single serotype with a wide tropism for neurons (AAV2/1, which has a mosaic capsid of serotypes 1 and 2) 28 for all viral constructs.
To ensure that the expression pattern was not due to the specifics of the injection, we injected multiple animals with the same large volume for each virus, and always used GFP-expressing rAAVs of similar titer (see Table S1 ) and the same coordinates in every case (see Methods for details). Figure 1B shows the result of injecting 400 nl of a virus expressing GFP from a ubiquitous CMV promoter (CMV-rAAV) into the MEC, note the widespread strong expression throughout the various layers of the entorhinal cortex, as well as subiculum and parasubiculum.
In order to obtain viruses capable of driving expression as specific as the EDGE transgenic animals in wildtype brains one must first find a minimal viral promoter which is capable of 6 robust expression only when paired with a heterologous enhancer. This is complicated by the fact that the viral ITRs themselves have transcriptional activity [29] [30] [31] , as can be seen by the weak nonspecific expression obtained from a GFP construct with neither a promoter nor an enhancer ( Figure 1C ). Note that the expression levels in 1C are far below those seen with other viruses: each panel in Figure 1 has been differentially processed to aid visualization, see Figure S1 for details. To minimize this issue, we reversed the orientation of the expression cassette relative to the ITRs such that the sense strand was under the influence of the 3' ITR, which we attenuated by putting WPRE 32 between the 3'ITR and the enhancer (see schematics in 1C, D). This revised design substantially reduced the background expression in other layers, enabling us to recapitulate MEC LII-specific expression in a wildtype mouse ( Fig   1D) with a mutated minimal CMV promoter (CMV*) 33 . Roughly similar results were obtained with three different minimal promoters ( Figure S2 ) but we selected CMV* for all subsequent experiments (and hereafter simply refer to the enhancer) as it was the smallest minimal promoter that yielded layer-specific EDGE with low background expression. The specificity of the expression of this virus as compared to a nonspecific CMV-rAAV virus is quantified in Figure 1E . While still clearly much more specific than the CMV-rAAV, the quantification of MEC13-53 rAAV does not look as specific as the figure panels because our conservative manual quantification for this initial characterization (see Methods) did not distinguish between weak "background" label (such as that seen without a promoter) and strong specific labelling.
MEC13-53 EDGE rAAVs express specifically in layer II stellate cells in wildtype mice
The precise anatomical boundaries of the various layers of EC can be easily visualized by using the neuron-specific stain NeuN 34 , confirming the robust layer-specific expression of the MEC13-53 rAAV (Fig 2A) . All the GFP+ cells were also NeuN positive, confirming the specificity of the virus to neurons (data not shown). Much less intense background GFP expression was observed in other layers as well in both the MEC13-53 rAAV (Figure 2A , inset) and in the rAAV backbone with the same design and minimal promoter but lacking the enhancer (Fig 2B, inset), which did not strongly label any cells. As for cell specificity, within LII of MEC there are two major classes of excitatory principal neurons, RE+ stellate cells and CB+ pyramidal cells 26, 35 , with RE label providing a sharp boundary between MEC and parasubiculum 25, 26 (see arrows in Figure 2C , inset). We therefore performed immunohistochemical analysis comparing these markers to viral GFP and found that for the MEC13-53 rAAV, 100% (594/594) of GFP+ neurons in layer II were RE+ ( Figure 2C , E), while less than 1% (5/655) of them were CB+ ( Figure 2D , E).
In contrast, with the ubiquitous CMV-rAAV, only 34% (319/929) of GFP+ LII neurons were RE+ while 10.5% (142/1353) were CB+. Thus, the MEC13-53 rAAV drives transgene expression specifically in a particular subset of excitatory neurons in EC of wildtype mice, i.e. RE+ EC LII neurons (stellate cells in MEC), avoiding the adjacent CB+ pyramidal cells, just as in the transgenic lines based upon the same enhancer.
EDGE rAAVs drive neuronal subtype-specific expression across species
While recapitulation of the expression pattern of the corresponding transgenic mouse line nicely illustrates the specificity of EDGE rAAVs, perhaps the greatest utility of viral vectors is that they can conceivably be used in wildtype animals of any species. Because evolutionary conservation is one of the hallmarks of enhancers 36 , we posited that the murine MEC13-53 enhancer might be similarly cell-specific in the rat MEC. As seen in Figure 3A , stereotactic injections of 1000 nl of the MEC13-53 rAAV into rat MEC leads to cell-type specificity as specific as that seen in the mouse (if anything, it is more specific). Figure 3A shows the MEC13-53 rAAV counterstained with NeuN, demonstrating that GFP expression is almost exclusive to MEC LII (as quantified in Figure 3E ), while the few labelled neurons seen in the virus without the enhancer have no layer II specificity ( Figure 3B ), much as was the case in mouse ( Figure   2B ). Similarly, 100% (1803/1803) of GFP+ neurons in rats injected with MEC13-53 rAAVs were RE+ ( Figure 3C, F) , while only 1.8% (29/1589) were CB+ ( Figure 3D, F) , demonstrating that in both species this virus drives expression exclusively in one (RE+) subtype of EC LII excitatory neurons but not the other (CB+), even though the two subtypes are intermingled 26 . This further demonstrates that the observed specificity results from the enhancer rather than the injection site, as does the fact that this specific expression pattern is seen throughout the dorso-ventral and medio-lateral axes of the MEC (Figure S3 C). It is interesting to note that while these two markers are largely mutually exclusive, there are reports of a very small subpopulation of RE+ neurons that are also CB+ 25, 37 .
EDGE rAAVs recapitulate the expression pattern of their respective transgenic lines
To examine whether all EDGE rAAVs can specify gene expression in particular subsets of cells, we created EDGE rAAVs with several other enhancers. While not all enhancers that worked as transgenic lines worked in rAAVs, roughly half ( Figure 4 , left column) did indeed appear to recapitulate the specificity of the corresponding EDGE lines (Figure 4 , right column).
Remarkably, the MEC13-104 rAAV (Fig 4A) recapitulates even the sparse labeling of a small subset of LIII neurons (arrows) seen in MEC13-104, a mainly LII-specific enhancer line (Fig 4B) , and the converse is true for LEC13-8, a mainly EC LIII-specific line (compare 4C to 4D). This suggests that the sparse label in the minor layer seen in the EDGE transgenic lines is specifically driven by the enhancer, rather than by random integration site-dependent mosaicism. Thus, the relative densities of the layer-specific label appear to be enhancer-specific, suggesting that the minority of cells which express outside of their primary layer may not be "noise". Ongoing experiments seek to verify whether there are any functional distinctions between the cells labeled by the various enhancers, which often express in different subsets of what has been thought of as a single neuronal cell type, e.g. stellate cells.
Discussion
Our prior work showed that identification of cis-regulatory elements uniquely active in finely dissected cortical subregions allows one to generate genetic tools specific to cells in that subregion, an approach we call EDGE (Enhancer-Driven Gene Expression) 11 . Here we show that one can use the same approach to make rAAVs with similar specificity in both mouse and rat, provided the vector and minimal promoter's innate transcriptional activity is minimized.
This clearly cross-validates the initial identification of enhancers in our prior work 11 : while transgenic lines might show highly specific expression patterns purely due to insertional effects (though not the same patterns multiple times, as we saw), rAAVs typically do not insert into the genome 38 , so they cannot show such effects. In other words, while the precise functional significance of the enhancers presented here remains unknown, they clearly are "true" enhancers, reflecting some genetic subgroup of excitatory neurons in the entorhinal cortex of wildtype mice and rats. Taken together, these data lead to two very interesting conclusions: 1) the number of genetically-defined subgroups of neurons may be far greater than generally assumed (though this assumption has recently been challenged 39, 40 ) , and 2) this approach conceivably provides a path towards neuronal subtype-specific transgene expression in any species.
That enhancers drive expression similarly in both transgenic lines and viruses is not a particularly surprising result. It has been known for decades that enhancers drive cell-specific expression [41] [42] [43] . For instance, enhancers related to the 6 homeobox genes related to the fly distal-less gene 44 (Dll in fly, Dlx in vertebrates) have been shown to play a crucial role in morphogenesis in a variety of species 45 . Due to their central role in development such homeobox genes have been under intense scrutiny by geneticists working in a variety of systems [46] [47] [48] [49] for decades, leading to a highly detailed understanding of these loci and the cisregulatory elements controlling their transcription. One such enhancer in the Dlx 5/6 gene cluster has been shown to be critical to the development of interneurons in particular 50 , though. A recent paper 22 used this enhancer element in a viral vector to obtain interneuronspecific expression in a variety of species, nicely showing that enhancers can be used to drive expression in viral vectors. However, as is true for most genetically-defined enhancers active early in development, Dlx5/6 drives expression across broad classes of neurons (e.g. interneurons in general) throughout the brain, rather than to particular interneuronal subclasses and/or subregions. In addition, there are several (mostly unpublished) reports of using cis-regulatory elements identified by various means to drive expression in neuronal subtypes 23, 43, 51, 52 .
Thus, the most important aspect of these data is not that enhancers can work in viral vectors, it is the illustration of the promise of applying modern genomic techniques to the study of the precise neural circuitry of the vertebrate brain. The striking diversity of enhancers found in these tiny subregions of cortex (the numbers of unique enhancers in each was comparable to those found for entire organs) may indicate a similar diversity of neuronal cell types in the brain. However, the relationship between enhancers and cell types remains unclear. Indeed, the expression patterns we obtain are arguably more specific than our current understanding of neuronal cell type 1, 2 . For instance, stellate cells are a generally-accepted excitatory neuronal cell type of the medial entorhinal cortex 53 . They are characterized mainly by their stellate morphology, the fact they project to the hippocampus, and their expression of RE but not CB 25, 26 55, 56 . It will likely take years of anatomical, molecular, and physiological characterization of these tools to disentangle such questions, so for our current purposes the most important consideration is that these enhancer-based molecular genetic tools remain true to type, as appears to be the case. For instance, both the 7 MEC13-53 transgenic lines 11 as well as the MEC13-53 rAAVs completely avoid expression in CB+ pyramidal cells, the other major kind of MEC LII excitatory neurons intercalated with stellate cells 25, 26 , shown in Figures 2 and 3 , clearly differentiating between distinct subtypes of excitatory neurons within the same cortical layer in both multiple transgenic lines and rAAVs in two species.
It should be noted, however, that specificity is never absolute, especially with viral vectors.
While we obtain neuronal subtype-specific results with large injections into the entorhinal cortex ( Figure S3 ), it is likely that any cell type in other brain regions which express the transcription factor(s) appropriate for a particular enhancer would be labeled as well.
Moreover, presumably many more cells are infected than show strong GFP label, and there is a baseline level of transcription from other elements in the viral construct (i.e. the minimal promoter and the ITRs). This implies that multiple infections of an EDGE rAAV in any cell could lead to discernible nonspecific transgene expression without involvement of the enhancer at all ( Figure 1C, 2B ). Viral expression is thus not all-or-nothing, but the difference between background and enhancer-driven expression levels can be quite marked ( Figure S1 ). This background expression can be quite problematic with enzymes such as recombinases, or when complementing replication-competent viruses (e.g. ∆G-rabies 57 ), but is likely not an issue with transgenes whose effects vary roughly linearly with their expression levels, such as chemogenetic 6 and/or optogenetic tools 7 .
Thus, identification of the active enhancers of a mere four cortical subregions of the mouse brain has led to a variety of viral tools for circuit analysis that appear to work across species, at least in rodents. Since one can do this on any species with a reasonably well-annotated genome, one could conceivably develop tools for anatomically specific "circuit-breaking" experiments in any species. Thus, not only will circuit-specific tools greatly facilitate our understanding of normal and pathological brain function, they could in time possibly provide novel circuit-specific therapeutic avenues. For example, it has been known for decades that preclinical stages of Alzheimer's disease (AD) are characterized by neuronal loss and accumulation of neurofibrillary tangles in the superficial layers of trans-entorhinal cortex 58 , a region roughly equivalent to rodent MEC layer II. In addition, intracellular amyloid-β is found specifically in MEC layer II reelin-positive neurons in human AD pathology and rodent disease models 59 . Given the emerging consensus that AD may progress trans-synaptically 60, 61 , it is conceivable that one could use something like a MEC13-53 rAAV to deliver therapeutic agents directly to the presumed pre-α cells. More generally, it is possible that the reason that many neurological and neuropsychiatric disorders are resistant to drug therapy is that they are imbalances in particular neural circuits, not diseases of the entire brain. A drug having tropism for multiple circuits (as most do) would then by definition produce unwanted side effects: it may do the right thing in the right circuit, but it does the wrong thing to normal circuits.
Results like those presented here allow us to hope that we may one day be able to design interventions with the required specificity to match the complexity of diseases of the brain. 
Legends
Methods
Construct and rAAV preparation. All rAAV constructs were generated on backbone plasmid pAAV-CMV-MCS-WPRE-hGH PolyA (modified by cloning WPRE after the MCS in pAAV-MCS, Agilent, USA). Control rAAV constructs were generated as follows: for ubiquitously expressing rAAV construct (CMV-rAAV) without a region-specific enhancer was generated by cloning the enhanced GFP (GFP) into the MCS of the pAAV-CMV-MCS-WPRE-hGH PolyA. For the promoterless construct for testing the transcriptional activity of ITRs, CMV promoter was removed from CMV-rAAV. To synthesize EDGE rAAV constructs, the CMV promoter, MCS and hGH PolyA sequences except WPRE were removed from pAAV-CMV-MCS-WPRE hGH PolyA.
An expression cassette consisting of a hybrid promoter (composed of a region specific enhancer and minimal promoter), GFP and PolyA sequence were then subcloned into the plasmid in reverse orientation relative to the ITRs, to circumvent any promoter activity from the 5'ITR. The expression cassette in the reverse orientation was cloned into the plasmid upstream of the WPRE which thus minimized the promoter activity from the 3'ITR. Various EDGE rAAV constructs with the revised design were generated by cloning murine enhancers obtained from our initial enhancer screen such as MEC-13-53, MEC-13-104 or LEC-13-8 and different minimal core promoters such as a variant of CMV (CMV*) 33 , FGF4 62 , HSV-TK or HSP68 11, 36 into the expression cassette in the reverse orientation. Sequences of the EDGE rAAVs, the region specific enhancers and the minimal promoters used in the study are given below. Plasmids were maintained in the Stbl3 E. coli strain (ThermoFisher, USA) to avoid ITRmediated recombination. Enhanced GFP, WPRE, LEC-13-8 and minimal promoters were synthesised by Genscript, USA. Positive clones were confirmed by restriction digestion analyses and subsequently by DNA sequencing. Endotoxin-free plasmid maxipreps (Qiagen) were made for rAAV preparations. EDGE rAAVs were packaged in AAV serotype 2/1 (having a mosaic of capsid 1 and 2) 28 using Heparin column affinity purification 63 . Specifically, a pAAV construct generated as described above with AAV helper plasmids encoding the structural elements, were transfected into the AAV-293 cell line (Agilent, USA). The day before transfection, 7 x 10 6 AAV-293 cells were seeded into 150 mm cell culture plates in DMEM containing 10 % fetal bovine serum (ThermoFisher, USA) and penicillin/streptomycin. Co-transfection of plasmids such as pAAVcontaining the transgene, pHelper, pRC (Agilent, USA) and pXR1 (NGVB, IU, USA) was carried out next day. After 7 hours, the medium was replaced with fresh 10 % FBS-containing DMEM.
The AAV-293 cells were cultured for two days following transfection to allow rAAV synthesis to occur. The AAV-293 cells filled with virus particles were scraped from the cell culture plates, then isolated by centrifugation at 200 x g. The cell pellet was then subjected to lysis using 150 mM NaCl-20 mM Tris pH 8 buffer containing 10 % sodium deoxycholate. The lysate was treated with Benzonase nuclease HC (Millipore) for 45 minutes at 37 o C. Benzonase-treated lysate was centrifuged at 3000 x g for 15 mins and the clear supernatant then subjected to HiTrap® Heparin High Performance (GE) affinity column chromatography using a peristaltic pump 63 . The elute from the Heparin column was concentrated using Amicon Ultra centrifugal filters (Millipore). The titer of the resultant viral stock was determined by quantitative PCR as approximately 10 11 infectious particles/ml. Stereotaxic Injections and Perfusions. For rat experiments, the rAAVs were stereotactically injected into three-four month old Long-Evans rats. Injections were performed with 1 µl rAAV at a titer of ~1 x10 11 infectious particles/ml, into the MEC of the rats. The rats were deeply anaesthetized with isoflurane gas (induction with 5 % isoflurane (v/v), maintenance at 1 % isoflurane (v/v), airflow of 1200 ml/min). To maintain the body temperature of the animal, a heating pad at 37 o C was used.
Rats were injected subcutaneously with buprenorphine hydrochloride (Temgesic®, Indivior) and Metacam® (Boehringer Ingelheim Vetmedica) at the prescribed dosage. Local anaesthetic Bupivacaine hydrochloride (Marcain TM , AstraZeneca) was applied at the place of incision. The head was fixed to the stereotaxic frame with ear bars, and the skin at the incision site was disinfected with 70 % ethanol and iodine before the incision was made using a sterile surgical scalpel blade. After incision, the mouthpiece and ear bars were adjusted so that bregma and lambda were aligned horizontally. Mediolateral coordinates were measured from the midsagittal sinus, anterior-posterior coordinates were measured from posterior transverse sinus, and dorso-ventral coordinates were measured from the surface of the brain. A craniotomy was made around the approximate coordinate, and precise measurements were made with the glass capillary/Hamilton needle (HAMI7762-06) used for virus injection. Coordinates for rat injections were 4.6 mm lateral, 0.2 mm anterior to the posterior transverse sinus and 2.6 mm deep, with the glass capillary/needle lowered at 10 o pointing towards the nose. A single injection of 1 µl virus was conducted at a speed of 100 nl/min using a nanoliter injector (Nanoliter2010, World Precision Instruments, Sarasota, FL, USA), controlled by a microsyringe pump controller (Micro4 pump, World Precision Instruments). After completion of the injection, the capillary was retracted after a 10 minute delay, to give the virus time to diffuse. Finally, the wound was rinsed with saline and the skin was sutured. The animals were left to recover in a heating chamber, before being returned to their home cage. Next day Metacam was administered orally and their health was checked daily. Acquisition of images were done at similar capture settings in confocal microscope. For figure   S1 the post-acquisition modifications were carried out similarly using Zen 2012 software. For figure 1 (B-D) images were modified differently to visualize the distinct GFP expression pattern (details in Figure S1 ). For the post-acquisition processing, confocal czi. images were opened in Zen 2012, and visualized with intensity range indicator. The intensity histogram for the green channel was altered until the optimum intensity was visualized (as displayed by the range indicator). Identical changes in the intensity levels were applied to the other confocal images captured using the same settings for comparison ( Figure S1 ). Table S1 . Titers of the important rAAVs synthesized for the current study. Quantitative PCR was carried out for the titration of the rAAVs. See the methods sections for detailed protocol.
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Sequences of the minimal promoters used in the study. CCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCGTCGGGCGACCTTTGGTCGC  CCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCTG  CGGCCGCACGCGTAAGGACAGGGAAGGGAGCAGTGGTTCACGCCTGTAATCCCAGCAATTTGGGA  GGCCAAGGTGGGTAGATCACCTGAGATTAGGAGTTGGAGACCAGCCTGGCCAATATGGTGAAACCC  CGTCTCTACCAAAAAAACAAAAATTAGCTGAGCCTGGTCATGCATGCCTGGAATCCCAACAACTCGG  GAGGCTGAGGCAGGAGAATCGCTTGAACCCAGGAGGCGGAGATTGCAGTGAGCCAAGATTGTGCC  ACTGCACTCCAGCTTGGTTCCCAATAGACCCCGCAGGCCCTACAGGTTGTCTTCCCAACTTGCCCCTT  GCTCCATACCACCCCCCTCCACCCCATAATATTATAGAAGGACACCTAGTCAGACAAAATGATGCAAC  TTAATTTTATTAGGACAAGGCTGGTGGGCACTGGAGTGGCAACTTCCAGGGCCAGGAGAGGCACTG  GGGAGGGGTCACAGGGATGCCACCCGTTTACTTGTACAGCTCGTCCATGCCGAGAGTGATCCCGGC  GGCGGTCACGAACTCCAGCAGGACCATGTGATCGCGCTTCTCGTTGGGGTCTTTGCTCAGGGCGGA  CTGGGTGCTCAGGTAGTGGTTGTCGGGCAGCAGCACGGGGCCGTCGCCGATGGGGGTGTTCTGCT  GGTAGTGGTCGGCGAGCTGCACGCTGCCGTCCTCGATGTTGTGGCGGATCTTGAAGTTCACCTTGAT  GCCGTTCTTCTGCTTGTCGGCCATGATATAGACGTTGTGGCTGTTGTAGTTGTACTCCAGCTTGTGCC  CCAGGATGTTGCCGTCCTCCTTGAAGTCGATGCCCTTCAGCTCGATGCGGTTCACCAGGGTGTCGCC  CTCGAACTTCACCTCGGCGCGGGTCTTGTAGTTGCCGTCGTCCTTGAAGAAGATGGTGCGCTCCTGG  ACGTAGCCTTCGGGCATGGCGGACTTGAAGAAGTCGTGCTGCTTCATGTGGTCGGGGTAGCGGCTG  AAGCACTGCACGCCGTAGGTCAGGGTGGTCACGAGGGTGGGCCAGGGCACGGGCAGCTTGCCGGT  GGTGCAGATGAACTTCAGGGTCAGCTTGCCGTAGGTGGCATCGCCCTCGCCCTCGCCGGACACGCT  GAACTTGTGGCCGTTTACGTCGCCGTCCAGCTCGACCAGGATGGGCACCACCCCGGTGAACAGCTCC  TCGCCCTTGCTCACCATGGTGGGTTTACGAGGGTAGGAAGTGGTACGGAAAGTTGGTATAAGACAA  AAGTGTTGTGGAATTGCTCCAGGCGATCTGACGGTTCACTAAACGAGCTCTGCTTTTATAGGCGCCC  ACCGTACACGCCTAAAGCTTATACGAATTCTGTACTGATGAACAGCCTTGATTGGTGGCTGCCTGTG  ACAGCCAGCGTATGCTTCTTGGTCTCTTGTCTATTGTATTCTTACTGATCTATGAGTTATCTTGAGTGC  TCTCCTGAATGCGTATTCTTTAGTCCGGAATCGGATAAACCTGTGTCTCATTTATGCTACTCAGGAAA  CAACTTTCCCTAGGATCCCTACAGTCTTGAGCTATGCTTCTAAACTTCTCTGGCTCCCTCCAATTACAC  ACTTTCAGGTGTGCAACAGACACGGGACATCTAGAATGAACACTTACTCCTCTGTTGGGCTTTCTCTG  GGGACTGGGCAGGTATAGATATAAAAGCAATTTCTGAAGCATGTGTGTCTTCACTGACTGTGTTTTC  TACATGGTCCCATTGGTTAAGGCTACTGATTTGGGGTGGTCATTTTCTAAGGTTAGTCAAATGGCTCT  TTTGAAACTATTTCTGTTGGTGTGTTTGATATTTTCCTTAGGGAACAAAAGAGGCAGATGGGAAACG  ATCTCAAGCTACTCTTTGGGGCTTAGATACTGAGGACAAAACTCAGGGATGAGCATAAGAGGAAGC  CTTTGTGTGTGGGGGGGGGGGACCCCTGTGCTTCTGTCGTGAGGAACTTAGCACCTCAGAGCCACA  AGTGCACAGTCTAGAAGATCTTTATTAACCTTAAGTGGTCTTGTCATCTAGAGTAGATTTTGGCACCA  TTTTGAGGTTGTCAGAAAATTCCTTTTGGCATTCCACCGGAACCACAAAATATTTAGCAAAAATGACC  ACAGCGTGGAACTAATAGTGTGAGTAGTCTTATGATAAGCTTTGAAATTAGCTTCTTACCAAATTCCT  GCCGCCCCTAAAAACACCCAGCTGTTATTCTCATGCCTAGTTATCTATTATAATCATTAATATCAAATG  TCTTTAAGACTTGGAACATCAGAAAGAAAAAGAGGAGAAAGCAGAGAGTGTTTAGAACCTTAGCCC AATCTGTTTGGTGGGTGATGATATGTTTTGAAACTAAAAAGACTTTTTGAAGTGAGCTACCTGCAAG  ATGGACCTGACCAAACACAGGTTTTGGTGTGAGCAGTGGCTGATGGTATCCCTAGGGGCTAAGTGT  ACTCCAAGTTCAGTGCTTATGTAAAACCCAGTAAGAGTACATCGCACGATGCAGCGCTTGCTGGGGC  TCAGGCTGACTGACTACAATGGCTGGCATTTTCCCTGTTCTCACACTTACAAAAATAAAATCAGAAAG  CATGAGAGGCTGCAGAAAGACATCTGGTAGCACAACACGAAGACATTTATCGAAAGGATGCCTTTT  TCCCTCTTAAAAGCTGCAAAAACGTTTGTGGCATCCCATCTCATCTAATCAGTGACAAATCCGTGAGA  GGATGGCAGAGGATTGAAGTAAATATTTCTCTTGTGTTAAATGTGAGCCTAACTTCATCTTTCTGCCG  AGTTGTGCTTCAGTGACTCGGTTGTGCAAAGTCATGGTGTAGATTCTTAATTAGAGAGGCATCATCA  TGAAGGTAGATAGAGAAGCATAAAGAGGGATGATGATACACAGGGCCAAACGGACGTGGGTCCAC  ACTTGTGTCTTTCAGAGCATCTTACAGACGCTTGACTTATCATGTCTTTTGCAGAACACCGTTTGCTTA  ATGATAGTTCTTGCATTCAATTTTGATGTCATCTTAATGATATTCAGTATTAAAGACAAGCCTGAATTT  TTGCTCATGCTATTAAACCTCTCAGTTAGAGCTGGGTGAGGTACATAGAATTAAAAACAAAAGGGCC  TACTAGACTCAGATGCCTGACATGGAATTAATCAGTTAAACAGTTTATAGGGCTCTTTCAGCATCTAC  AAAAGTTTCATAGATGTGTTGTGTGATTTACACAATGAGGACAGCTGTCATATCTGTAAACTCAGTG  GGCCATGGGGAGATGTACAACAGGTGACTTCCAATGTCACACCAAGTATCAGCTTGAAAATTACTCA  ACTTTTAGGAAATTTGCCTTGAATTGTCTTCAAGTGGCTAGATCTCTTACCATTGCTAGTGAGTCTGC  CCATTATATCCTTTTTCTCTGATACCAGCCGTTTTTCAGTTATAAGACCTGAAAAAATTATGTGTAATT  ATTATATTTGCACAGGTTTTAGGACATTGCTTTCTATGTATATTTATAGGTTGTCGACCTGCAGAAGC  TTTCGAGAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGCTC  CTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCA  TTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAAC  GTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCA  GCTCCTTTCCGGGACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGC  CCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAATCATC  GTCCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCC  CTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGT  CTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCAGATCTCTGATTTTGT  AGGTAACCACGTGCGGACCGAGCGGCCGCAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCT  GCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGC  GGCCTCAGTGAGCGAGCGAGCGCGCAGCTGCCTGCAGGGGCGCCTGATGCGGTATTTTCTCCTTAC  GCATCTGTGCGGTATTTCACACCGCATACGTCAAAGCAACCATAGTACGCGCCCTGTAGCGGCGCAT  TAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCG  CTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGG  GGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTTGGGTGAT  GGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTT  TAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGGCTATTCTTTTGATTTATA  AGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAAT  TTTAACAAAATATTAACGTTTACAATTTTATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATA  GTTAAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCA  TCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCAC  CGAAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAAT  GGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCT  AAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAA  AGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCT GTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTG  GGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTC  CAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGA  GCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAG  CATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTG  CGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGG  GGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCG  TGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACT  CTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGC  TCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTA  TCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCA  GGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTA  ACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGAT  CTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAG  CGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGC  TTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTT  TTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTT  AGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGG  CTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGG  CGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACC  GAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGA  CAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAAC  GCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTC  GTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTG  CTGGCCTTTTGCTCACATGT   pAAV-CMV-GFP (CMV-rAAV)   CCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCGTCGGGCGACCTTTGGTCGC  CCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCTG  CGGCCGCACGCGTCTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGG  AGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATT  GACGTCAATAATGACGTATGTTCCCATAGTAACGTCAATAGGGACTTTCCATTGACGTCAATGGGTG  GAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTAT  TGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCT  ACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAA  TGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGT  TTGTTTTGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATG  GGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCC  TGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCGGAT  TCGAATCCCGGCCGGGAACGGTGCATTGGAACGCGGATTCCCCGTGCCAAGAGTGACGTAAGTACC  GCCTATAGAGTCTATAGGCCCACAAAAAATGCTTTCTTCTTTTAATATACTTTTTTGTTTATCTTATTTC  TAATACTTTCCCTAATCTCTTTCTTTCAGGGCAATAATGATACAATGTATCATGCCTCTTTGCACCATTC  TAAAGAATAACAGTGATAATTTCTGGGTTAAGGCAATAGCAATATTTCTGCATATAAATATTTCTGCA  TATAAATTGTAACTGATGTAAGAGGTTTCATATTGCTAATAGCAGCTACAATCCAGCTACCATTCTGC TTTTATTTTATGGTTGGGATAAGGCTGGATTATTCTGAGTCCAAGCTAGGCCCTTTTGCTAATCATGT  TCATACCTCTTATCTTCCTCCCACAGCTCCTGGGCAACGTGCTGGTCTGTGTGCTGGCCCATCACTTTG  GCAAAGAATTGGGATTCGAACATCGATTGAATTCCCACCATGGTGAGCAAGGGCGAGGAGCTGTTC  ACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCC  GGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAA  GCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTAC  CCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGC  ACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACC  CTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAA  GCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAA  GGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCA  GAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCC  CTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGG  ATCACTCTCGGCATGGACGAGCTGTACAAGTAAGGATCCTCTAGAGTCGACCTGCAGAAGCTTGCCT  CGAGAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGCTCCTT  TTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCATTT  TCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAACGT  GGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGC  TCCTTTCCGGGACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCC  GCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAATCATCGT  CCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTT  CGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTT  CGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCAGATCTACGGGTGGCATC  CCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTC  CTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGG  GGTGGTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAAC  CAAGCTGGAGTGCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCT  CCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTT  TTTGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACTCCTAATCTCAGGTGATCTA  CCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAACCACTGCTCCCTTCCCTGTCCTTCTGA  TTTTGTAGGTAACCACGTGCGGACCGAGCGGCCGCAGGAACCCCTAGTGATGGAGTTGGCCACTCC  CTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCC  CGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGCTGCCTGCAGGGGCGCCTGATGCGGTATTTTCTC  CTTACGCATCTGTGCGGTATTTCACACCGCATACGTCAAAGCAACCATAGTACGCGCCCTGTAGCGG  CGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGC  GCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAAT  CGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTTGG  GTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCAC  GTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGGCTATTCTTTTGA  TTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACG  CGAATTTTAACAAAATATTAACGTTTACAATTTTATGGTGCACTCTCAGTACAATCTGCTCTGATGCC  GCATAGTTAAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCC  CGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTC  ATCACCGAAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATA ATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATT  TTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTG  AAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCC  TTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACG  AGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGT  TTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCA  AGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAA  AAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAAC  ACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACA  TGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACG  AGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACT  TACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTG  CGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCG  GTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGA  GTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATT  GGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAA  GGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCAC  TGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTG  CTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACT  CTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGT  AGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCA  GTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGAT  AAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTA  CACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGG  CGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGG  AAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGAT  GCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCT  TTTGCTGGCCTTTTGCTCACATGT   pAAV-GFP (Promoterless-rAAV)   CCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCGTCGGGCGACCTTTGGTCGC  CCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCTG  CGGCCGCTCGAACATCGATTGAATTCCCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGT  GGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG  GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCG  TGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCA  CATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC  TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAA  CCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGT  ACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACT  TCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCC  CCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAA  AGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCT  CGGCATGGACGAGCTGTACAAGTAAGGATCCTCTAGAGTCGACCTGCAGAAGCTTGCCTCGAGAAT CAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGCTCCTTTTACGCTA  TGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCATTTTCTCCTCCT  TGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGT  GTGCACTGTGTTTGCTGACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCG  GGACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGG  ACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAATCATCGTCCTTTCCTT  GGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTC  AATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCG  CCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCAGATCTACGGGTGGCATCCCTGTGAC  CCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAA  ATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTA  TGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTG  GAGTGCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTC  AGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTTTTTGGTAG  AGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACTCCTAATCTCAGGTGATCTACCCACCTTG  GCCTCCCAAATTGCTGGGATTACAGGCGTGAACCACTGCTCCCTTCCCTGTCCTTCTGATTTTGTAGG  TAACCACGTGCGGACCGAGCGGCCGCAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCG  CGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGC  CTCAGTGAGCGAGCGAGCGCGCAGCTGCCTGCAGGGGCGCCTGATGCGGTATTTTCTCCTTACGCA  TCTGTGCGGTATTTCACACCGCATACGTCAAAGCAACCATAGTACGCGCCCTGTAGCGGCGCATTAA  GCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTC  CTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGC  TCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTTGGGTGATGGT  TCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAA  TAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGGCTATTCTTTTGATTTATAAG  GGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTT  AACAAAATATTAACGTTTACAATTTTATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTT  AAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCC  GCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGA  AACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGT  TTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAA  TACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGG  AAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTT  TTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGT  TACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAA  TGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCA  ACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCAT  CTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCG  GCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGG  GATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGT  GACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTC  TAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCT  CGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTAT  CATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCA GGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTA  ACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGAT  CTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAG  CGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGC  TTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTT  TTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTT  AGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGG  CTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGG  CGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACC  GAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGA  CAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAAC  GCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTC  GTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTG  CTGGCCTTTTGCTCACATGT pAAV-mCMV*-GFP (Enhancerless rAAV). Note that the expression cassette in the reverse orientation with respect to the ITRs. CCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCTG  CGGCCGCACGCGTAAGGACAGGGAAGGGAGCAGTGGTTCACGCCTGTAATCCCAGCAATTTGGGA  GGCCAAGGTGGGTAGATCACCTGAGATTAGGAGTTGGAGACCAGCCTGGCCAATATGGTGAAACCC  CGTCTCTACCAAAAAAACAAAAATTAGCTGAGCCTGGTCATGCATGCCTGGAATCCCAACAACTCGG  GAGGCTGAGGCAGGAGAATCGCTTGAACCCAGGAGGCGGAGATTGCAGTGAGCCAAGATTGTGCC  ACTGCACTCCAGCTTGGTTCCCAATAGACCCCGCAGGCCCTACAGGTTGTCTTCCCAACTTGCCCCTT  GCTCCATACCACCCCCCTCCACCCCATAATATTATAGAAGGACACCTAGTCAGACAAAATGATGCAAC  TTAATTTTATTAGGACAAGGCTGGTGGGCACTGGAGTGGCAACTTCCAGGGCCAGGAGAGGCACTG  GGGAGGGGTCACAGGGATGCCACCCGTTTACTTGTACAGCTCGTCCATGCCGAGAGTGATCCCGGC  GGCGGTCACGAACTCCAGCAGGACCATGTGATCGCGCTTCTCGTTGGGGTCTTTGCTCAGGGCGGA  CTGGGTGCTCAGGTAGTGGTTGTCGGGCAGCAGCACGGGGCCGTCGCCGATGGGGGTGTTCTGCT  GGTAGTGGTCGGCGAGCTGCACGCTGCCGTCCTCGATGTTGTGGCGGATCTTGAAGTTCACCTTGAT  GCCGTTCTTCTGCTTGTCGGCCATGATATAGACGTTGTGGCTGTTGTAGTTGTACTCCAGCTTGTGCC  CCAGGATGTTGCCGTCCTCCTTGAAGTCGATGCCCTTCAGCTCGATGCGGTTCACCAGGGTGTCGCC  CTCGAACTTCACCTCGGCGCGGGTCTTGTAGTTGCCGTCGTCCTTGAAGAAGATGGTGCGCTCCTGG  ACGTAGCCTTCGGGCATGGCGGACTTGAAGAAGTCGTGCTGCTTCATGTGGTCGGGGTAGCGGCTG  AAGCACTGCACGCCGTAGGTCAGGGTGGTCACGAGGGTGGGCCAGGGCACGGGCAGCTTGCCGGT  GGTGCAGATGAACTTCAGGGTCAGCTTGCCGTAGGTGGCATCGCCCTCGCCCTCGCCGGACACGCT  GAACTTGTGGCCGTTTACGTCGCCGTCCAGCTCGACCAGGATGGGCACCACCCCGGTGAACAGCTCC  TCGCCCTTGCTCACCATGGTGGGTTTACGAGGGTAGGAAGTGGTACGGAAAGTTGGTATAAGACAA  AAGTGTTGTGGAATTGCTCCAGGCGATCTGACGGTTCACTAAACGAGCTCTGCTTTTATAGGCGCCC  ACCGTACACGCCTAAAGCTTATACGAATTCCCCGGGGATCCTCTAGAGTCGACCTGCAGAAGCTTTC  GAGAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGCTCCTTT  TACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCATTTT  CTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAACGTG  GCGTGGTGTGCACTGTGTTTGCTGACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCT CCTTTCCGGGACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCG  CTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAATCATCGTC  CTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTC  GGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTC  GCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCAGATCTCTGATTTTGTAGGT  AACCACGTGCGGACCGAGCGGCCGCAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGC  GCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCC  TCAGTGAGCGAGCGAGCGCGCAGCTGCCTGCAGGGGCGCCTGATGCGGTATTTTCTCCTTACGCAT  CTGTGCGGTATTTCACACCGCATACGTCAAAGCAACCATAGTACGCGCCCTGTAGCGGCGCATTAAG  CGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCC  TTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCT  CCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTTGGGTGATGGTT  CACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAAT  AGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGGCTATTCTTTTGATTTATAAGG  GATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTA  ACAAAATATTAACGTTTACAATTTTATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTA  AGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCG  CTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAA  ACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTT  TCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAAT  ACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGG  AAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTT  TTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGT  TACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAA  TGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCA  ACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCAT  CTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCG  GCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGG  GATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGT  GACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTC  TAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCT  CGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTAT  CATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCA  GGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTA  ACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGAT  CTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAG  CGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGC  TTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTT  TTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTT  AGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGG  CTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGG  CGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACC  GAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGA  CAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAAC GCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTC 
CCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCGTCGGGCGACCTTTGGTCGC
GTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTG CTGGCCTTTTGCTCACATGT
Sequences of the EC region-specific enhancers used in the study.
Sequence of MEC13-53
AACCTATAAATATACATAGAAAGCAATGTCCTAAAACCTGTGCAAATATAATAATTACACATAATTTT TTCAGGTCTTATAACTGAAAAACGGCTGGTATCAGAGAAAAAGGATATAATGGGCAGACTCACTAG  CAATGGTAAGAGATCTAGCCACTTGAAGACAATTCAAGGCAAATTTCCTAAAAGTTGAGTAATTTTC  AAGCTGATACTTGGTGTGACATTGGAAGTCACCTGTTGTACATCTCCCCATGGCCCACTGAGTTTACA  GATATGACAGCTGTCCTCATTGTGTAAATCACACAACACATCTATGAAACTTTTGTAGATGCTGAAAG  AGCCCTATAAACTGTTTAACTGATTAATTCCATGTCAGGCATCTGAGTCTAGTAGGCCCTTTTGTTTTT  AATTCTATGTACCTCACCCAGCTCTAACTGAGAGGTTTAATAGCATGAGCAAAAATTCAGGCTTGTCT  TTAATACTGAATATCATTAAGATGACATCAAAATTGAATGCAAGAACTATCATTAAGCAAACGGTGT  TCTGCAAAAGACATGATAAGTCAAGCGTCTGTAAGATGCTCTGAAAGACACAAGTGTGGACCCACG  TCCGTTTGGCCCTGTGTATCATCATCCCTCTTTATGCTTCTCTATCTACCTTCATGATGATGCCTCTCTA  ATTAAGAATCTACACCATGACTTTGCACAACCGAGTCACTGAAGCACAACTCGGCAGAAAGATGAA  GTTAGGCTCACATTTAACACAAGAGAAATATTTACTTCAATCCTCTGCCATCCTCTCACGGATTTGTCA  CTGATTAGATGAGATGGGATGCCACAAACGTTTTTGCAGCTTTTAAGAGGGAAAAAGGCATCCTTTC  GATAAATGTCTTCGTGTTGTGCTACCAGATGTCTTTCTGCAGCCTCTCATGCTTTCTGATTTTATTTTT  GTAAGTGTGAGAACAGGGAAAATGCCAGCCATTGTAGTCAGTCAGCCTGAGCCCCAGCAAGCGCTG  CATCGTGCGATGTACTCTTACTGGGTTTTACATAAGCACTGAACTTGGAGTACACTTAGCCCCTAGG  GATACCATCAGCCACTGCTCACACCAAAACCTGTGTTTGGTCAGGTCCATCTTGCAGGTAGCTCACTT  CAAAAAGTCTTTTTAGTTTCAAAACATATCATCACCCACCAAACAGATTGGGCTAAGGTTCTAAACAC  TCTCTGCTTTCTCCTCTTTTTCTTTCTGATGTTCCAAGTCTTAAAGACATTTGATATTAATGATTATAAT  AGATAACTAGGCATGAGAATAACAGCTGGGTGTTTTTAGGGGCGGCAGGAATTTGGTAAGAAGCTA  ATTTCAAAGCTTATCATAAGACTACTCACACTATTAGTTCCACGCTGTGGTCATTTTTGCTAAATATTT  TGTGGTTCCGGTGGAATGCCAAAAGGAATTTTCTGACAACCTCAAAATGGTGCCAAAATCTACTCTA  GATGACAAGACCACTTAAGGTTAATAAAGATCTTCTAGACTGTGCACTTGTGGCTCTGAGGTGCTAA  GTTCCTCACGACAGAAGCACAGGGGTCCCCCCCCCCCACACACAAAGGCTTCCTCTTATGCTCATCCC  TGAGTTTTGTCCTCAGTATCTAAGCCCCAAAGAGTAGCTTGAGATCGTTTCCCATCTGCCTCTTTTGTT  CCCTAAGGAAAATATCAAACACACCAACAGAAATAGTTTCAAAAGAGCCATTTGACTAACCTTAGAA  AATGACCACCCCAAATCAGTAGCCTTAACCAATGGGACCATGTAGAAAACACAGTCAGTGAAGACA  CACATGCTTCAGAAATTGCTTTTATATCTATACCTGCCCAGTCCCCAGAGAAAGCCCAACAGAGGAG  TAAGTGTTCATTCTAGATGTCCCGTGTCTGTTGCACACCTGAAAGTGTGTAATTGGAGGGAGCCAGA  GAAGTTTAGAAGCATAGCTCAAGACTGTAGGGATCCTAGGGAAAGTTGTTTCCTGAGTAGCATAAA  TGAGACACAGGTTTATCCGATTCCGGACTAAAGAATACGCATTCAGGAGAGCACTCAAGATAACTCA  TAGATCAGTAAGAATACAATAGACAAGAGACCAAGAAGCATACGCTGGCTGTCACAGGCAGCCACC  AATCAAGGCTGTTCATCAGTACA   Sequence of MEC13-104   AGAATTTTGGCTGAGATCTTTATATTCTTCATATTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT  CTCTCTCTTTCCCTGGAAAGAATAAAAAACAACAAAACAACTTTGGGGATATTTAAATGCAAAATAG CTCCAAATTATTAAAAATGTCTTCACAGTTTTGCCGACATGCATTTAGCCATGAGGTACAGAGAATGA  AATCAGTGATGCTTTTCTTGATCCAGAATACATTTTCATTTTGTCTTTCATGCACTCTAGCCAGATGAG  TGGGCAGCTATTTTGAAGGTTGACAATCTGCTCCAAGTCTTGGAAAACAGGCAAGTCCCCCAAGAAA  GAACGAAGAGATTTGCGATCTTAATTCAGAGTAGGGAGAACACATGAGTTTTAGTAATAAACCAAC  ACTTGAGAGAGAGAAAAAAAACCCCTAGCATTGCTGTTTATTGATGTTGTAATATTGGGGAGGTTGT  TGAGTGTGCCTTCGTCTCTCCACTTTTAGTATGGGTTCATGGACATTTCCCAGAGTTGTGCTGTGATC  GGTGAGCACATTAAATACTTAGCTTTGTACCTGACACATTTCCTGACCCCCAACACTTGTATTTCCCAT  GTCCTGTGCCCTCTTCTCCACTGCTCATGCTTGTTTTTTTACTATACTGACTCCTTTTTCTATCCTGAAA  CAAAGAGATGACTGACCGACCACCCTGACTTCGGATGACTATGGGAAACTGTGGTACCACAAACAC  ACCTTGTTGGGGGGCAGCATGAGTTAGCTATTCATCACTATTGGACAAATAGGAACACCCTGGGTAT  TACTAAATAGAAGAACTGTTAGGGGAAATGCTCCATCAATCCCAGATACCCCACCACAAAGCCTTGT  GCCATCACTGGAATCTGTTGACCTACTTACGAAATCTCTAATTCTATTCCTGATAGCCTATAATTAGG  ATGATCTGAAATAGCCCGAAAACATTCCGTGCCAGCATTTATCCCCAAAGGCAAGTCGAGAAACCTT  CAATAAGGCCTTTTCTGAAATTTGCTTTTGAGTCAACAGATTTGGCAATATTTTAACTTGTAGGCAGA  CAGAAAGGAGAAAGGAAAGAAAAGAGACAACTAGACAGAAGTCAGAACGGGAGATGAGAAAAGG  GGAAGGAAGGAAAGAAGATAGAGGAACGGGAGGGAGAGCTAAATGATCTCACTTTTGTACATTTC  ATCAAAATGTAGAGCAAGCTCTTGCCCAAATTTATTAGCAGTTATCTCAGATATGTGAAGAAAGGTT  GAGAGAGTCACTCCAAATAAAACAATCCCAATAAATAAATAAACCAAACAAATCTTTATGTCAACAC  AGCTTCTGCTTTTGCGTTTGGCTGTAGTATGAGAAAAAAAAATCACTTTGAAAAAAGCAAGCATGAA  TAGAACTGTATTTCAACCCCAAATGTCCCCCTACCCTCTCCCCCCCGCCCCTGACAAATAGAGCTTCA  GAAACGCAACACCTATCAAATATTTCCTCAGAAATGCCAGATTGCTGGGATTTTAAAGAGTTCTACTT  TTTTTTCTTCCCTTTTTGACATTTAGACAGATTGAGTTTGAGAGAGGAAGTGACTCGGAGTCCAGCCT  GCCCCGCACCACTGTCAGAGGAAATAACCGAAGCAAAATGAAGTGATAATATACTGTAGAATATTTA  ACAGAAAGAGTGAAGCAGGGGCTTGGGGGGTGGGGAGTGGATGGCAATCTGAGAATATACAACT  GATCCCCAAAATAGATGCAGTCTCCTGTGCCCGAGCAGATGCCAACTACAGAGGATCGTGAAACGG  TAGAATTACCTTGCTCTGTGGGCTGTGTGTTGACATATGAACACCGACTCCCCAATAGTCAGAGGAG  CTGGCTCTTTTCCCTCCAGTCTCTGTTAGGCTTTGTCACAGAGCCTGCCAACTTTTCCCTTTCTGTATAT  TCGTCAGTGAAAGAGCTGGTAAGTGACCACCGTAATGGCTGCAGCATGTTGCTGTGTGGGTCTTGA  CAGAAAACTACAACCCTGGGCCCTTCTGTCACAGCGTGAATGAAATCAGAAAGTCCAAGGGAGGAT  ATTAGCAAGGCTCTTTCCATTCTGGAGAAGACTCAAGGCGATAAGGGACATTGAGATTTCCCACCCA  AGGAAAGAGTCATAAATAGGGCGATGAAGGAAAAACACAACCCCCTTCTGCGAGTTTAATGAGAAA  ACGGCCACCTCCTGGGGAATGGGGTAGAAAGCTGAGGTGCTGTCTTAACAGCCTGCAAAAGTTGAA  ACATTGACAAAACAAGCTTTCTTCATCTGCTGAAAACAGGGAACTGTTTTAAAGAACCCCCCACCTCT  TATTCACAAAGGAGTAGAGACTGACACTTGGAGAAGGCCGATTTTTTCCTTTTCTCTATGTGAATAGT  TGAAAACTTTCTCTTTTCTTTCCTGGAAAATTTCTCCTCCATCTATGTGCTGACCTTCCTGATGTATGAC  TGACTCTCTTTTACCCACCAAGTCTGGGGCAATCACCAAAACAGAGGCTCGGGGACAGTTTCGTCCT 
